Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment

Lipids in Health and Disease

Volumn 9, Issue 1, 2010, Pages

  Marsillach, Judit ^a   Aragonès, Gerard ^a   Mackness, Bharti ^a   Mackness, Michael ^a   Rull, Anna ^a   Beltrán Debón, Raúl ^a   Pedro Botet, Juan ^b   Alonso Villaverde, Carlos ^a   Joven, Jorge ^a   Camps, Jordi ^a  

^a INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXIDE; PHOSPHOLIPID; PROCOLLAGEN N PROTEINASE; TYPE III PROCOLLAGEN N PEPTIDE; UNCLASSIFIED DRUG; ARYLDIALKYLPHOSPHATASE; PROTECTIVE AGENT;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBON TETRACHLORIDE-INDUCED LIVER INJURY; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME GLYCOSYLATION; FEMALE; FIBROGENESIS; GEL ELECTROPHORESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; INFLAMMATION; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FIBROSIS; MALE; MOLECULAR WEIGHT; NONHUMAN; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; RAT; STEATOSIS; WESTERN BLOTTING; WISTAR RAT; ANIMAL; CASE CONTROL STUDY; CHEMICAL ANALYSIS; CHEMISTRY; CHRONIC DISEASE; GENETIC PROCEDURES; GLYCOSYLATION; LIVER DISEASE; METABOLISM;

ANIMALS; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CHEMISTRY TECHNIQUES, ANALYTICAL; CHRONIC DISEASE; GLYCOSYLATION; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; LIVER DISEASES; MOLECULAR PROBE TECHNIQUES; MOLECULAR WEIGHT; OXIDATIVE STRESS; PROTECTIVE AGENTS; RATS;

EID: 77952048387     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-9-46     Document Type: Article

References (54)

1. Furlong CE, Suzuki SM, Stevens RC, Marsillach J, Richter RJ, Jarvik GP, Checkoway H, Samii A, Costa LG, Griffith A, Roberts JW, Yearout D, Zabetian CP: Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact 2010 in press. doi:10-1016/j.cbi.2010.03.033
2. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN: Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lip Res 2005, 46:1239-1247.
3. Mackness MI, Arrol P, Durrington PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993, 104:129-135.
4. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M: Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995, 96:2882-2891.
5. Mackness B, Quarck R, Verreth W, Mackness M, Holvoet P: Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 2006, 26:1545-1550.
6. Camps J, Marsillach J, Rull A, Alonso-Villaverde C, Joven J: Interrelationships between paraoxonase-1 and monocyte chemoattractant protein-1 in the regulation of hepatic inflammation. Adv Exp Med Biol 2010, 660:5-18.
7. Negre-Salvayre A, Dousset N, Ferretti G, Bacchetti T, Curatola G, Salvayre R: Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med 2006, 41:1031-1040.
8. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ: High density lipoproteins inhibit cytokine induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995, 15:1987-1994.
9. Birjmohun RS, Van Leuven SI, Levels JHM, Van't Veer C, Kuivenhoven JA, Meijers JCM, Levi M, Kastelein JJP, Poll T Van der, Stroes ESG: High-density lipoprotein attenuates inflammation and coagulation on endotoxin challenge in humans. Arterioscler Thromb Vasc Biol 2007, 27:1153-1158.
10. Simpson KJ, Henderson NC, Bone-Larson CL, Lukacs NW, Hogaboam CM, Kunkel SL: Chemokines in the pathogenesis of liver disease: so many players with poorly defined roles. Clin Sci (Lond) 2003, 104:47-63.
11. Parola M, Bellomo G, Robino G, Barrera G, Dianzani MU: 4- Hydroxynonenal as a biological signal: molecular basis and pathophysiological implications. Antioxidant Redox Signaling 1999, 1:255-284.
12. Zamara E, Novo E, Marra F, Gentilini A, Romanelli RG, Caligiuri A, Robino G, Tamagno E, Aragno M, Danni O, Autelli R, Colombatto R, Dianzani MU, Pinzani M, Parola M: 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol 2004, 40:60-68.
13. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM: HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001, 21:481-488.
14. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M: Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 2004, 318:680-683.
15. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM: Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002, 106:484-490.
16. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M: Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 2003, 34:774-784.
17. Ng DS, Chu T, Esposito B, Hui P, Connelly PW, Gross PL: Paraoxonase-1 deficiency in mice predisposes to vascular inflammation, oxidative stress, and thrombogenicity in the absence of hyperlipidemia. Cardiovasc Pathol 2008, 17:226-232.
18. Leviev I, Negro F, James RW: Two alleles of the human paraoxonase gene produce different amounts of mRNA. Arterioscler Thromb Vasc Biol 1997, 17:2935-2939.
19. Reuben A: Alcohol and the liver. Curr Opin Gastroenterol 2007, 23:283-291.
20. Marsillach J, Bertran N, Camps J, Ferré N, Riu F, Tous M, Coll B, Alonso- Villaverde C, Joven J: The role of circulating monocyte chemoattractant protein-1 as a marker of hepatic inflammation in patients with chronic liver disease. Clin Biochem 2005, 38:1138-1140.
21. Ferré N, Camps J, Prats E, Vilella E, Paul A, Figuera L, Joven J: Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002, 48:261-268.
22. Ferré N, Marsillach J, Camps J, Mackness B, Mackness M, Riu F, Coll B, Tous M, Joven J: Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J Hepatol 2006, 45:51-59.
23. Marsillach J, Ferré N, Vila MC, Lligoña A, Mackness B, Mackness M, Deulofeu R, Solá R, Parés A, Pedro-Botet J, Joven J, Caballeria J, Camps J: Serum paraoxonase-1 in chronic alcoholics: Relationship with liver disease. Clin Biochem 2007, 40:645-650.
24. Zhang C, Peng W, Jiang X, Chen B, Zhu J, Zang Y, Zhang J, Zhu T, Qin J: Transgene expression of human PON1 Q in mice protects the liver against CCl4 induced injury. J Gene Med 2008, 10:94-100.
25. Ustundag B, Bahcecioglu IH, Sahin K, Duzgun S, Koca S, Gulcu F, Ozercan IH: Protective effect of soy isoflavones and activity levels of plasma paraoxonase and arylesterase in the experimental nonalcoholic steatohepatitis model. Dig Dis Sci 2007, 52:2006-2014.
26. Gassó M, Rubio M, Varela G, Cabré M, Caballería J, Alonso E, Deulofeu R, Camps J, Giménez A, Pajares M, Parés A, Mato JM, Rodés J: Effects of Sadenosylmethionine on lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis. J Hepatol 1996, 25:200-205.
27. Usui S, Hara Y, Hosaki S, Okazaki M: A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lip Res 2002, 43:805-814.
28. Magoori K, Kang MJ, Ito MR, Kakuuchi H, Ioka RX, Kamataki A, Kim DH, Asaba H, Iwasaki S, Takei SA, Sasaki M, Usui S, Okazaki M, Takahashi S, Ono M, Nose M, Sakai J, Fujino T, Yamamoto TT: Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E. J Biol Chem 2003, 278:11331-11336.
29. Marsillach J, Mackness B, Mackness M, Riu F, Beltrán R, Joven J, Camps J: Immunochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic Biol Med 2008, 45:146-157.
30. Havel RJ, Eder HA, Bragdon JH: The distribution and chemical composition of ultracentrifugally isolated lipoproteins in human serum. J Clin Invest 1955, 34:1345-1350.
31. Marsillach J, Camps J, Ferré N, Beltran R, Rull A, Mackness B, Mackness M, Joven J: Paraoxonase-1 is related to inflammation, fibrosis and PPARδ in experimental liver disease. BMC Gastroenterol 2009, 9:3.
32. Reddy ST, Wadleigh DJ, Grijalva V, Ng CJ, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM: Human paraoxonase-3 is an HDLassociated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 2001, 21:542-547.
33. Lagrost L, Barter P: Effects of various non-esterified fatty acids on the transfer of cholesteryl esters from HDL to LDL induced by the cholesteryl ester transfer protein. Biochim Biophys Acta 1991, 1085:209-216.
34. Lagrost L, Athias A, Gambert P, Lallemant C: Comparative study of phospholipid transfer activities mediated by cholesteryl ester transfer protein and phospholipid transfer protein. J Lip Res 1994, 35:825-835.
35. Damen J, Regts J, Scherphof G: Transfer of [14C]phosphatidylcholine between liposomes and human plasma high-density lipoprotein. Partial purification of a transfer-stimulating factor using a rapid transfer assay. Biochim Biophys Acta 1982, 712:444-452.
36. Robert K, Nehmé J, Bourdon E, Delcayre C, Delabar JM, Janel N: Cystathionine beta synthase deficiency promotes oxidative stress, fibrosis, and steatosis in mice liver. Gastroenterology 2005, 128:1405-1415.
37. Comporti M, Signorini C, Arezzini B, Vecchio D, Monaco B, Gardi C: Isoprostanes and hepatic fibrosis. Mol Aspects Med 2008, 29:43-49.
38. Phung N, Pera N, Farrell G, Leclercq I, Hou JY, George J: Pro-oxidantmediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. Int J Mol Med 2009, 24:171-180.
39. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, La Du BN: Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999, 26:892-904.
40. James RW, Deakin SP: The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med 2004, 37:1986-1994.
41. Cabana VG, Reardon CA, Feng N, Neath S, Lukens J, Getz GS: Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. J Lip Res 2003, 44:780-792.
42. Blanco-Vaca F, Escolà-Gil JC, Martínez-Campos JM, Julve J: Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lip Res 2001, 42:1727-1739.
43. Ribas V, Sánchez-Quesada JL, Antón R, Camacho M, Julve J, Escolà-Gil JC, Vila L, Ordóñez-Llanos J, Blanco-Vaca F: Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Circ Res 2004, 95:789-797.
44. Bergmeier C, Siekmeier R, Gross W: Distribution spectrum of paraoxonase activity in HDL fractions. Clin Chem 2004, 50:2309-2315.
45. Moren X, Deakin S, Liu ML, Taskinen MR, James RW: HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress. J Lip Res 2008, 49:1246-1253.
46. Miller JP: Dyslipoproteinaemia of liver disease. Baillieres Clin Endocrinol Metab 1990, 4:807-832.
47. Huuskonen J, Olkkonen VM, Jauhiainen M, Ehnholm C: The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis 2001, 155:269-281.
48. Lewis GF, Reader DJ: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005, 96:1221-1232.
49. Cho KH, Park SH, Park SE, Kim YO, Choi I, Kim JJ, Kim JR: The function, composition, and particle size of high-density lipoprotein were severely impaired in an oliguric phase of hemorrhagic fever with renal syndrome patients. Clin Biochem 2008, 41:56-64.
50. Kontush A, Therond P, Zerrad A, Couturier M, Négre-Salvayre A, de Souza JA, Chantepie S, Chapman MJ: Preferential sphingosine-1-phosphate enrichment and sphinglomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol 2007, 27:1843-1849.
51. de Souza JA, Vindis C, Hansel B, Négre-Salvayre A, Therond P, Serrano CV Jr, Chantepie S, Salvayre R, Bruckert E, Chapman MJ, Kontush A: Metabolic syndrome features small, apolipoprotein A-I poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis 2008, 197:84-94.
52. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN: Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 1999, 19:2214-2225.
53. Deakin S, Leviev I, Gamaraschi M, Calabresi L, Franceschini G, James RW: Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by high affinity, saturable, desorption mechanism. J Biol Chem 2002, 277:4301-4308.
54. Liu Y, Mackness B, Mackness M: Comparison of the ability of paraoxonases 1 and 3 to attenuate the in vitro oxidation of low-density lipoprotein and reduce macrophage oxidative stress. Free Radic Biol Med 2008, 45:743-748.